In 81% of blood samples from patients with a history of COVID-19, the samples had the antibody that attacked the ACE2.
In participants with no history of COVID-19, no antibodies were created to attack the ACE2 enzyme.
“If we show that the whole hypothesis is right, that this interference of ACE2 really does cause long COVID, then it opens up many potential treatments,†said Arthur.